Alx Oncology Holdings (ALXO) EBIT (2019 - 2026)
Alx Oncology Holdings (ALXO) posted EBIT of -$19.0 million for Q1 2026, up 17.61% sequentially from -$23.0 million in Q4 2025, and up 40.4% YoY from -$13.5 million in Q1 2025.
Alx Oncology Holdings (ALXO) EBIT (2019 - 2026) Analysis & Trends
Alx Oncology Holdings has reported EBIT for 8 years, with the latest figure at -$19.0 million in Q1 2026.
- Quarterly EBIT rose 40.4% year-over-year to -$19.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$91.2 million (up 33.22% YoY) and the FY2025 annual result came in at -$104.0 million, up 26.99% from the prior year.
- EBIT improved to -$19.0 million in Q1 2026 per ALXO's latest filing, from -$23.0 million in the prior quarter.
- Over five years, EBIT peaked at -$19.0 million in Q1 2026 and troughed at -$53.3 million in Q3 2023.
- A 5-year average of -$33.1 million and a median of -$32.2 million in 2022 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2026: EBIT sank 107.31% in 2022, then jumped 40.4% in 2026.
- Over 5 years, EBIT stood at -$32.2 million in 2022, then sank by 49.05% to -$48.0 million in 2023, then surged by 36.25% to -$30.6 million in 2024, then advanced by 24.8% to -$23.0 million in 2025, then advanced by 17.61% to -$19.0 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$19.0 million, -$23.0 million, and -$22.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Alx Oncology Holdings | 270.90 Mn | 270.90 Mn | - | -18.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.03 Mn |
| Mar 31, 2026 | -18.97 Mn |
| Dec 31, 2025 | -23.02 Mn |
| Sep 30, 2025 | -22.53 Mn |
| Jun 30, 2025 | -26.65 Mn |
| Mar 31, 2025 | -31.82 Mn |
| Dec 31, 2024 | -30.61 Mn |
| Sep 30, 2024 | -32.57 Mn |
| Jun 30, 2024 | -41.53 Mn |
| Mar 31, 2024 | -37.76 Mn |
| Dec 31, 2023 | -48.02 Mn |
| Sep 30, 2023 | -53.28 Mn |
| Jun 30, 2023 | -36.78 Mn |
| Mar 31, 2023 | -32.20 Mn |
| Dec 31, 2022 | -32.22 Mn |
| Sep 30, 2022 | -36.68 Mn |
| Jun 30, 2022 | -33.79 Mn |
| Mar 31, 2022 | -24.75 Mn |
| Dec 31, 2021 | -28.47 Mn |
| Sep 30, 2021 | -24.58 Mn |